ABEO Stock Forecast: Abeona Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Abeona Therapeutics, Inc. is $16. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Abeona Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (74): Sales and profits are climbing, and climbing faster than before.
Momentum (29): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ABEO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ABEO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $18 |
| 9 Nov 2026 | Cantor Fitzgerald | Maintains | Overweight | $30 → $19 |
| 18 Sept 2026 | Cantor Fitzgerald | Maintains | Overweight | $28 → $30 |
| 17 Sept 2026 | Roth Capital | Initiates | Buy | $17 |
| 14 Aug 2026 | Oppenheimer | Maintains | Outperform | $22 → $21 |
| 28 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 19 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2025 | Oppenheimer | Maintains | Outperform | — |
| 16 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2025 | Oppenheimer | Assumes | Outperform | $19 |
| 16 May 2025 | Stifel | Maintains | Buy | — |
| 30 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Mar 2025 | Oppenheimer | Initiates | Outperform | — |
| 19 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ABEO.
This page is one stock. Monday covers all of them.
ABEO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ABEO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Abeona Therapeutics, Inc. returned −42.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ABEO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 4.2×
- Price / book
- 1.1×
- EV / EBITDA
- —
Cheaper than 25% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 63.3%
- Operating margin
- —
- Net margin
- —
Higher than 76% of US stocks
- Return on equity
- −42.1%
- Return on assets
- −22.5%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Abeona Therapeutics, Inc. has a market value of $149.2M and an enterprise value of $20.0M.
Revenue in the twelve months to 30 June 2026: $25.5M. The latest quarter grew 2745.0% year on year.
Net income over the same four quarters: −$62.9M, a −246.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$81.5M, after $5.1M of capital spending.
Abeona Therapeutics, Inc. employs 226 people — $113K of revenue per employee.
Data provided by Twelve Data
ABEO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ABEO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Abeona Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ABEO
What is the ABEO stock price forecast for 2026-2027?
The median 12-month analyst price target for Abeona Therapeutics, Inc. is $16, with estimates ranging from $7.5 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ABEO stock a buy right now?
Of the 7 analysts covering Abeona Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Abeona Therapeutics, Inc. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ABEO?
As at 21 Nov 2026, Abeona Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (74 of 100).
Will ABEO stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $16, and Ticker Nerd's factor model ranks Abeona Therapeutics, Inc. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ABEO stock forecast for 2030?
No analyst covering Abeona Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.5 to $21 over the next 12 months.
How has ABEO stock performed over the past year?
Abeona Therapeutics, Inc. returned -42.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Abeona Therapeutics, Inc. do?
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for serious rare diseases. Its current portfolio centers on ZEVASKYN, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, alongside a pipeline of adeno-associated virus-based programs for ophthalmic and other genetic disorders.
About Abeona Therapeutics, Inc.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for serious rare diseases. Its current portfolio centers on ZEVASKYN, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, alongside a pipeline of adeno-associated virus-based programs for ophthalmic and other genetic disorders. The company also develops engineered T-cell and viral vector technologies designed to address high-unmet-need conditions in oncology and rare disease settings. Abeona Therapeutics operates from Cleveland, Ohio, with a fully integrated cGMP manufacturing facility that supports commercial production and clinical development activities. The company serves the biotechnology and advanced therapies market, where it plays a specialized role in translating genetic medicine into targeted treatments for patients with limited therapeutic options.
CEO Dr. Vishwas Seshadri M.B.A., Ph.D. · 226 employees · United States · https://www.abeonatherapeutics.com